Brief: Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children

Takeda Pharmaceutical

19/02/2026 17:40

Feb 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

POSITIVE PHASE 3 DATA DEMONSTRATE POTENTIAL FOR ENTYVIO® (VEDOLIZUMAB) TO ADDRESS TREATMENT GAP FOR CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS

TAKEDA PHARMACEUTICAL CO LTD: VEDOLIZUMAB'S SAFETY PROFILE WAS GENERALLY CONSISTENT WITH ITS KNOWN SAFETY PROFILE IN ADULTS

Source text: ID:nBw5ssxjSa

Further company coverage: 4502.T

 ((Reuters.Briefs@thomsonreuters.com;))